Table 1 Patients’ demographic characteristics and tumour features.
Refractory (n = 25) | Sensitive (n = 43) | |
|---|---|---|
Age, median in years (range) | 65 (52–80) | 69 (44–79) |
Gender | ||
Female | 11 (44.0%) | 13 (30.2%) |
Male | 14 (56.0%) | 30 (69.8%) |
ECOG performance status (PS) | ||
0 | 8 (32.0%) | 22 (51.2%) |
1 | 17 (68.0%) | 21 (48.8%) |
Histology | ||
SCLC | 22 (88.0%) | 37 (86.0%) |
LCNEC | 2 (8.0%) | 3 (7.0%) |
NEC undifferentiated | 1 (4.0%) | 3 (7.0%) |
Tumor stage | ||
LD | 5 (20.0%) | 6 (14.0%) |
ED | 20 (80.0%) | 37 (86.0%) |
Liver | 10 (50.0%) | 14 (37.8%) |
Brain | 4 (20.0%) | 3 (8.1%) |
Liver + Brain | 3 (15.0%) | 6 (16.2%) |
Treatment free interval, median in days (range) | 20 (0–57) | 123 (61–820) |
Prior treatment | ||
Chemotherapy | 24 (96.0%) | 43 (100%) |
Chemotherapy + ICI | 1 (4.0%) | 0 |
Type of chemotherapy | ||
Cisplatin + Etoposide | 4 (16.0%) | 13 (30.2%) |
Carboplatin + Etoposide | 21 (84.0%) | 30 (69.8%) |
Prior radiotherapy | ||
No | 19 (76.0%) | 13 (30.2%) |
Yes | 6 (24.0%) | 30 (69.8%) |
